gliquidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antihyperglycaemics	1302	33342-05-1

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

gliquidone
glurenorm
beglynor
gliquidone calcium
gliquidone monosodium
gliquidone sodium

Molecular weight: 527.64
Formula: C27H33N3O6S
CLOGP: 5.06
LIPINSKI: 2
HAC: 9
HDO: 2
TPSA: 121.88
ALOGS: -5.38
ROTB: 6

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,MAPK7,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK	16
kinase-selectivity-class	AXL,BRAF,CDK9,EIF2AK3,GRK2,MAPK12,MAPK7,PDK1,PDK4,STK33,TEK,TTK	12
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	18.664		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
rat-kpuu-brain	Rat brain Kpuu	0.032	%	High	1

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Stevens-Johnson syndrome	123.65	65.85	29	451	29347	90598620
Status epilepticus	91.86	65.85	21	459	18853	90609114
Sopor	76.14	65.85	19	461	24625	90603342
Skin laceration	75.10	65.85	19	461	26016	90601951

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary nocardiosis	45.54	43.20	9	491	1803	42619032

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Stevens-Johnson syndrome	57.69	40.27	20	980	46881	110541418
Status epilepticus	52.90	40.27	17	983	31554	110556745
Sopor	50.46	40.27	17	983	36529	110551770
Skin laceration	47.78	40.27	16	984	33737	110554562
Pulmonary nocardiosis	44.49	40.27	9	991	2620	110585679

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10BB08	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sulfonylureas
MeSH PA	D007004	Hypoglycemic Agents

Related Drugs by ATC class:

A10BB Sulfonylureas 12 drugs

acetohexamide carbutamide chlorpropamide glibenclamide glibornuride gliclazide glimepiride glipizide glisoxepide metahexamide tolazamide tolbutamide

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.31	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sulfonylurea receptor 1, Kir6.2	Ion channel	Q09428 Q14654	ABCC8_HUMAN KCJ11_HUMAN	BLOCKER	Kd	9		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
D02430	KEGG_DRUG
C0061328	UMLSCUI
CHEBI:93416	CHEBI
CHEMBL383634	ChEMBL_ID
DB01251	DRUGBANK_ID
C010969	MESH_SUPPLEMENTAL_RECORD_UI
3308	INN_ID
C7C2QDD75P	UNII
91610	PUBCHEM_CID
25793	RXNORM
003974	NDDF
325249006	SNOMEDCT_US
395732008	SNOMEDCT_US
C7C2QDD75P	INXIGHT DRUGS

Pharmaceutical products:

None